ResMed Completes Acquisition of MEDIFOX DAN, a German Leader in Out-of-Hospital Care Management Software Solutions
- Acquisition expands ResMed’s SaaS business to Germany, first non-U.S. market
- Outpatient therapy services added to ResMed’s growing SaaS offering portfolio
- Purchase price of €958.6 million (US$997.5 million); deal will be accretive to non-GAAP diluted earnings per share
SAN DIEGO and HILDESHEIM, Germany, Nov. 22, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it has completed its €958.6 million acquisition of MEDIFOX DAN, a German leader in software solutions for a wide variety of out-of-hospital care providers.
MEDIFOX DAN is headquartered in Hildesheim, Germany, with over 700 employees. It now operates under its current brand within the ResMed SaaS business segment. Its administrative, financial, and operational solutions are mission-critical for out-of-hospital care providers, providing care documentation, personnel planning, administration, billing, and more – similar to the solutions of ResMed’s leading U.S. SaaS brands, MatrixCare and Brightree.
“We’re excited to have closed this important expansion of our SaaS business, and to officially welcome MEDIFOX DAN to our ResMed SaaS team and global ResMed family,” said ResMed CEO Mick Farrell. “MEDIFOX DAN is a German leader in software innovation, united with the rest of ResMed in its mission to improve tens of millions of people’s lives through technology. Today, its strong offerings and dedicated staff expand ResMed’s out-of-hospital SaaS business into new health sectors, and to build on our strong ResMed healthcare business in Germany, the world’s second largest healthcare market in per capita spending.”
“Starting today, we are continuing our success story as part of the ResMed family,” said MEDIFOX DAN Co-Managing Directors Dr. Thorsten Schliebe and Christian Städtler. “With ResMed, we have found an ideal partner –global leaders in digital health, cloud-based SaaS solutions with emphasis on innovation, data privacy and data security – with which we can continue to grow, develop, and provide our customers with secure, state-of-the-art software solutions and services, so they can navigate the challenges of their daily caregiving routines in the best possible way.”
ResMed intends to retain MEDIFOX DAN’s employees, locations, and business processes. MEDIFOX DAN will report into ResMed SaaS President Bobby Ghoshal.
About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.
About MEDIFOX DAN
The MEDIFOX DAN Group, headquartered in Hildesheim, Germany, currently employs over 700 people at nine locations nationwide and specializes in the development of innovative software solutions and services for professional and non-professional care, therapeutic practices and child, family, and youth welfare facilities. In addition, digital solutions for modern training and education management - both for professional care and family caregivers - expand the group's comprehensive product portfolio. What started as a small start-up developed into a firmly established software company. Besides holistic product solutions, MEDIFOX DAN has always been characterized by strong partnerships and innovative services. Behind MEDIFOX DAN stands a team of innovative minds, over 55 years of industry experience and cumulative expertise, that works every day to set trendsetting standards for digitization in the health and social care sector and to drive innovation forward. In short: We are more than just software.
For media
In Germany: resmedGER@allisonpr.com
Rest of world: Jayme Rubenstein, +1 508.769.8440, news@resmed.com
For investors
Amy Wakeham, +1 858.836.5000, investorrelations@resmed.com
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Giambattista Valli dazzles Barcelona during the Bridal Night19.4.2024 12:41:00 CEST | Press release
BARCELONA, Spain, April 19, 2024 (GLOBE NEWSWIRE) -- The most exclusive fashion show of the Barcelona Bridal Fashion Week charmed over 450 guests last night who enjoyed a unique show in the historic building of the Llotja de Mar. The Maison Giambattista Valli exclusively celebrated the runway debut of its bridal collection during the Bridal Night, the gala evening of the event organized by Fira de Barcelona with the support of the Catalan Ministry of Business and Labor. In an extraordinary show, Giambattista Valli's 30 creations shone with their own light. It was a culmination of silhouettes, representing a comprehensive exhibition of Mr. Valli’s concept of contemporary bridal dressing, inviting his audience to witness the manifestation of his vision, translated into a presentation that embodies the essence of individuality, sharing a dream and a celebration and love. The fashion show featured ten dresses from the third “Love Collection,” ten iconic silhouettes from the first and secon
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)19.4.2024 12:10:00 CEST | Press release
Alvotech, in agreement with Teva Pharmaceuticals, has signed an agreement with a strategic partner to bring to the U.S. market the newly FDA approved high-concentration interchangeable biosimilar to Humira®The agreement broadens patient access and further commitment to availability of vital biologics in the U.S. and globally Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today a long-term agreement with a strategic partner to further enhance access to Adalimumab-ryvk in the U.S. market, the newly U.S. Food and Drug Administration (FDA) approved high-concentration interchangeable biosimilar to Humira. “This new partnership agreement supports our financial guidance and reflects Alvotech’s strong commitment to increasing patient access to more affordable healthcare,” said Robert Wessman, Chairman and CEO of Alvotech. The current multi-product commercialization partnership between T
Vaccinologists Keith Klugman and Shabir Madhi Awarded Sabin’s Prestigious Gold Medal; Infectious Diseases Epidemiologist Nicole Basta Receives Rising Star Award19.4.2024 12:00:00 CEST | Press release
WASHINGTON, April 19, 2024 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute yesterday presented the Albert B. Sabin Gold Medal to physician-researchers Keith Paul Klugman and Shabir Ahmed Madhi, and its Rising Star award to infectious diseases epidemiologist Nicole Elaine Basta at a ceremony in the National Academy of Sciences building in Washington D.C. Klugman and Madhi received the Sabin Gold Medal, one of the highest recognitions for vaccinologists globally, for their seminal combined contributions to the development of vaccines against pneumonia and diarrheal disease – major causes of death in children in low- and middle-income countries (LMICs). Klugman first met his then-graduate student Madhi at South Africa’s University of the Witwatersrand (also known as Wits University), where Klugman established, and Madhi expanded, a now globally renowned infectious diseases research institute. Apart from pneumonia, their work focused on maternal and children’s vaccines including influenza,
Forløb af ordinær generalforsamling 202419.4.2024 11:59:58 CEST | pressemeddelelse
Investeringsforeningen Investin har i dag afholdt ordinær generalforsamling i henhold til tidligere offentliggjort dagsorden. Ledelsens beretning og årsrapporten for 2023, herunder de i januar 2024 udbetalte udlodninger samt bestyrelsens honorar for 2023 blev godkendt af generalforsamlingen. Alle de af bestyrelsen stillede forslag blev vedtaget, herunder overflytning af afdeling I&T Nordiske Aktier Large Cap og afdeling I&T Globale Aktier ESG Select samt vedtægtsændringer. Til bestyrelsen genvalgtes Kim Høibye, Jesper Lau Hansen, Henrik Vincents Johansen samt Tine Roed, og bestyrelsen konstituerede sig efterfølgende med Kim Høibye som formand. Som revisor for foreningen genvalgtes EY Godkendt Revisionspartnerselskab. Eventuelle henvendelser vedrørende denne meddelelse kan rettes til direktør Tage Fabrin-Brasted på tlf. 44 55 91 60. Med venlig hilsen Investeringsforeningen Investin Tage Fabrin-Brasted Direktør
Investeringsforeningen ValueInvest Danmark – Prospektopdatering19.4.2024 11:32:00 CEST | pressemeddelelse
Opdateret prospekt for Investeringsforeningen ValueInvest Danmark offentliggøres dags dato. Der er foretaget følgende opdateringer i prospektet: Indsættelse af regnskabstal for 2023 Prospektet er vedhæftet denne fondsbørsmeddelelse og kan endvidere downloades på www.valueinvest.dk eller rekvireres ved henvendelse til BI Management A/S, Bredgade 40, 1260 København K, tlf. 77 30 90 00. Med venlig hilsen BI Management A/S Martin Fjordlund Smidt Direktør Vedhæftet fil Prospekt IF ValueInvest Danmark 2024.04.19 FINAL clean inkl. bilag